Patent · US Expired

Antitumor antisense sequences directed against ribonucleotide reductase

US5998383A · kind A · utility

33Cited by
0References
31Claims
0Family size

Inventors

Key dates

Filing dateAug 1, 1997
Grant dateDec 7, 1999
Priority date—
Expiry dateAug 1, 2017

Classification

  • Technology area (CPC C)Chemistry; Metallurgy
  • CPC primaryC12N2799/027
  • WIPO fieldPharmaceuticals
  • WIPO sectorChemistry

Abstract

A synthetic antisense oligonucleotide comprising at least seven nucleotides or nucleotide analogues having a sequence complementary to the mRNA sequence of ribonucleotide reductase dimeric protein component R2 including SEQ ID Nos:1-102 is disclosed. A synthetic antisense oligonucleotide comprising at least seven nucleotides or nucleotide analogues having a sequence complementary to the mRNA sequence of ribonucleotide reductase dimeric protein component R1 including SEQ ID Nos:103-161 is also disclosed. The invention also discloses pharmaceutical compositions including the synthetic antisense oligonucleotides of the present invention and methods of using the antisense oligonucleotides to modulation proliferative cells including neoplastic cells.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.